GEMSTONE BIOTHERAPEUTICS, LLC
Cure-in-place polysaccharide biomaterial that solidifies in contact with wound beds to promote healing
- Sector
- Medtech
- Headquarters
- BALTIMORE, MD
- Founded
- 2013
- Latest Form D
- $700K, Oct 2016
- Total capital
- $2.7M
- Federal grants
- $449K
- 2 awards · 2018
- Rank in peer group#23 of 35
- Private capital raised
- $2.3M
- 2 Form D · last Oct 2016
- 120 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 5 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Development of Reformulated Hypertension Pharmaceuticals for Treatment of Diabetic Foot Ulcers$225K
- Federal grantNSF · Phase I · SBIR Phase I: Cure-in-Place Extracellular Matrix Replacement Scaffolds for Wound Healing$225K
- Private capital raisedForm D · SEC · 2nd filing$700K
- Private capital raisedForm D · SEC · 1st filing$1.6M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 35 peers
Line = medianMedtech · Material
- Federal grantsBelow median
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- David OrosDirector, PromoterNamed in SEC Form D filings
- GEOFF MACKAYDirectorNamed in SEC Form D filings
- George DavisExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Sharon GerechtDirectorNamed in SEC Form D filings
- Xin HuangDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 5- PendingCrosslinked Dextran-Based Hydrogels and Uses ThereofUSPTOApplication 62961403
- PendingExtracellular Matrices, Uses Thereof, and Methods of Making Extracellular MatricesUSPTOApplication 62867069
- PendingExtracellular Matrices, Uses Thereof, And Method For Making ExtracellularUSPTOApplication PCTUS2018067881
Show all 5 patent records
- Crosslinked Dextran-Based Hydrogels and Uses ThereofApplication 62961403Pending
- Extracellular Matrices, Uses Thereof, and Methods of Making Extracellular MatricesApplication 62867069Pending
- Extracellular Matrices, Uses Thereof, And Method For Making ExtracellularApplication PCTUS2018067881Pending
- Extracellular Matrices, Uses Thereof, and Methods of Making Extracellular MatricesApplication 62682011Pending
- Extracellular Matrix-Drug Conjugates, Uses Thereof, and Methods of Making Extracellular Matrix-Drug ConjugatesApplication 62611381Pending
Related companies, and why
- OSCILLOSCAPE, LLCSimilar federal contract value in Medtech · null in contracts
- PEARL DIAGNOSTICS, INC.Similar federal contract value in Medtech · null in contracts
- MAGNIFY BIOSCIENCES INC.Similar federal contract value in Medtech · null in contracts
- ZENFLOW, INC.Similar federal contract value in Medtech · null in contracts
- SIMPLYBREATHE L.L.C.Similar federal contract value in Medtech · null in contracts
- Biocogniv Inc.Similar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .